Of note, in the phase 3 BOLERO-2 study, everolimus in combination with the aromatase inactivator, exemestane, significantly improved PFS versus exemestane alone in postmenopausal women with hormone-receptor (HR)-positive advanced breast cancer who had relapsed or progressed on nonsteroidal aromatase inhibitors [4]. Here, CYP19A1 is linked to breast cancer.